0.8% per year for placebo (p = not significant)
#Camellia timi 61 full#
Heart failure: 0.8% per year for lorcaserin vs. UPDATED WITH COMMENTARY Aug// MUNICH Full details of the CAMELLIA-TIMI 61 cardiovascular outcomes study with the obesity drug lorcaserin ( Belviq, Eisai) have been reported here at.0.5% per year for placebo (p = not significant) 22 They stated that after weighing the evidence of.
Cardiovascular death: 0.5% per year for lorcaserin vs. They published results suggesting 462 participants reporting cancer with lorcaserin (n❆000 7.7) vs 423 cases with placebo (n❆000 7.1).TACTICS TIMI 18, NSTE-ACS, CAMELLIA TIMI 61, Obesity. Weight loss of ≥5%: 38.7% for lorcaserin vs. In the CAMELLIA-TIMI 61 cohort, a small increase in cancer was noted in the treatment group, which has led the FDA to request Eisai, the manufacturer. The Thrombolysis in Myocardial Infarction (TIMI) Study Group was initially established to. He has also served in leadership of trials of secondary prevention of cardiovascular disease as global PI of DECLARE TIMI 58, CAMELLIA TIMI 61, and DAPA.The primary efficacy outcome, major cardiovascular events, heart failure, or hospitalization for unstable angina or revascularization, occurred in 4.1% per year in the lorcaserin group compared with 4.2% per year in the placebo group (p = not significant). Since the condition for noninferiority was met, further analyses focused on superiority testing for cardiovascular efficacy. The primary safety outcome, major cardiovascular events (cardiovascular death, myocardial infarction, or stroke), occurred in 2.0% per year in the lorcaserin group compared with 2.1% per year in the placebo group (p for noninferiority < 0.001).
0 kommentar(er)
